The Cytonics Ambassador Program is how you become part of what Cytonics builds next. You'll get a personal link and drafted messages for sharing CYT-108 with the people in your life. Sign up below.
Joey Bose · President & CEO
Video coming soon
Sign up
Research partners
Why this matters
A $560B disease the industry has not yet modified.
Decades of single-target programs have not produced a disease-modifying therapy for osteoarthritis. The disease is multifactorial. CYT-108 is a genetically engineered, more potent version of the body’s own A2M protein, designed to address the cascade rather than any single enzyme.
500M+
People living with OAworldwide
$560B
Annual marketno disease-modifying therapy
10,000+
Patients treated with first-gen APICsafety record carried into CYT-108
Completed Q4 2025
Phase 1 trialno drug-related adverse events
From an ambassador
“As a patient who has personally benefited from the Cytonics A2M therapy, I asked if I could be a partner to help spread the word.”
Rener GracieCo-founder, Gracie University · Cytonics ambassador
